The company pegged its full-year sales for 2018 between $55.2 million and $55.4 million, up 15% from 2017. Analysts on Wall Street are expecting Si-Bone to post Q4 sales of $15.4 million and FY18 revenues of $55.1 million.
“Our fourth quarter and full year 2018 U.S. results demonstrate strong financial performance that is the result of improving reimbursement coverage, sales execution and leadership products. We are also increasing investment in our European markets to accelerate growth in international sales,” president, chairman & CEO Jeff Dunn said in prepared remarks.
“We are well positioned to deliver accelerating revenue growth and solid operational results while progressing forward with commercial payors, training more surgeons, clinical evidence leadership, adjunct product initiatives and positively impacting patient lives,” he added.
SIBN shares were trading at $19.95 apiece in mid-afternoon activity today, up +0.2%.
Nevro shares hold steady following Q4, FY18 prelims
The company said that it plans to report full-year sales for 2018 between $386.9 million and $387.4 million, up from $326.7 million in 2017. Analysts are expecting Q4 sales of $106.2 million and FY18 sales of $385.5 million.
NVRO shares were trading at $37.08 apiece in mid-afternoon activity today, down -0.9%.
Alphatec shares fall after prelims miss estimates
Analysts are expecting the company record Q4 sales of $26.9 million and FY18 sales of $93.2 million. The company pegged its FY19 sales between $98 million and $103 million.
Alphatec also announced today that its president & COO, Terry Rich, has resigned.
“Our preliminary revenue results for the fourth quarter mark an encouraging close to a transformative year,” chairman & CEO Pat Miles said in prepared remarks. “We expect continued investment in 2019 as we create an industry-leading portfolio. Through commercial launch of our 2018 alpha releases, and our exclusive neuromonitoring informatics solution, we are forming a clinically distinct, approach-based spine technology platform. I am as confident as ever that we are building an organic innovation machine and look forward to generating future market disruption.”
ATEC shares were trading at $2.05 apiece in mid-afternoon activity, down -6.4%.
Luminex tops consensus with Q4 prelims, shares rise
Analysts on Wall Street estimate that the company will post Q4 sales of $78 million and FY18 sales of $312.6 million.
The company forecasted FY19 sales to be between $337 million and $343 million. LMNX shares were trading at $23.94 apiece in mid-afternoon activity, up +3.6%.
Endologix’s Q4 prelims beat Wall Street estimates
For 2019, the company hopes to reel in $140 million in revenue. In a statement, Endologix said it has $24 million in cash as of Dec. 31.
The consensus pegged Q4 sales for Endologix at $31.1 million and FY18 revenues at $152.8 million. ELGX shares were trading at 63 cents apiece, up +6%.